Biocon Limited

rs,

1, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

₹ 11,550

& Ethical Behavior Core Values Collaboration, Team Work & Mutual Respect Biocon at a Glance ₹ 11,550 Cr | $ ~1.4 bn Revenue* ~16,500+ Total Employees* Rank #8 Among Top 10 Global Biotech Employers*

rs 8

se global talent pool of 5,500+ people 390+ patents granted Portfolio comprises 20 biosimilars 8 Commercial Products in Global Markets 5.5M+ Patients served Unique, fully integrated leading g

rs 1

products commercialized globally Hybrid model: Direct presence + Network of partners & distributors 1Two products are in-licensed i.e. Adalimumab & Etanercept Biosimilars: Leading global player with a

38%

y board ✓ $190M raised to date from syndicate of dedicated biotech investors. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility

23%

sed to date from syndicate of dedicated biotech investors. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience i

1 %

Q1 FY24 Consolidated (in ₹ Cr.) Q1 FY24 Q1 FY23 YoY % Total Revenue 3,516 2,217 Core EBITDA1 % Margin EBITDA % Margin Profit Before Tax % Margin Net Profit Net Profit Margin % 936 28%

28%

A1 % Margin EBITDA % Margin Profit Before Tax % Margin Net Profit Net Profit Margin % 936 28% 808 23% 184 5% 101 3% 661 31% 478 22% 197 9% 144 7% 59 42 69 (7) Biosimilars +10

5%

A % Margin Profit Before Tax % Margin Net Profit Net Profit Margin % 936 28% 808 23% 184 5% 101 3% 661 31% 478 22% 197 9% 144 7% 59 42 69 (7) Biosimilars +106% | Research +25%

3%

in Profit Before Tax % Margin Net Profit Net Profit Margin % 936 28% 808 23% 184 5% 101 3% 661 31% 478 22% 197 9% 144 7% 59 42 69 (7) Biosimilars +106% | Research +25% | Generic

31%

t Before Tax % Margin Net Profit Net Profit Margin % 936 28% 808 23% 184 5% 101 3% 661 31% 478 22% 197 9% 144 7% 59 42 69 (7) Biosimilars +106% | Research +25% | Generics 15% Gro

22%

ax % Margin Net Profit Net Profit Margin % 936 28% 808 23% 184 5% 101 3% 661 31% 478 22% 197 9% 144 7% 59 42 69 (7) Biosimilars +106% | Research +25% | Generics 15% Growth across

Research

2

Research

Discovery Services Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities Development and Manufacturing Services – Small Molecules Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions Secure U.S. FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects

Research

Dedicated Centers Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows Scaling up Manufacturing Services Development and Manufacturing Services – Large Molecules Drive an integrated approach for biologics development and manufacturing to provide a one-stop- shop capability from drug discovery to commercial manufacturing for biologics Accelerate capacity build-up Operational Excellence Focus on customer delivery through operational excellence People Develop strong leaders and managers while offering all employees career- long learning opportunities Environmental, Social and Governance (ESG) Committed to operating in a responsible and sustainable manner. Q1 FY24 Highlights Financial Highlights: Q1 FY24 Consolidated (in ₹ Cr.) Q1 FY24 Q1 FY23 YoY % Total Revenue 3,516 2,217 Core EBITD